| Literature DB >> 35196494 |
Andrea Vogel1, Katharina Martin2, Klara Soukup2, Angela Halfmann2, Martina Kerndl1, Julia S Brunner1, Melanie Hofmann1, Laura Oberbichler1, Ana Korosec1, Mario Kuttke1, Hannes Datler1, Markus Kieler1, Laszlo Musiejovsky1, Alexander Dohnal3, Omar Sharif4, Gernot Schabbauer5.
Abstract
Dendritic cells (DCs) induce peripheral T cell tolerance, but cell-intrinsic signaling cascades governing their stable tolerogenesis remain poorly defined. Janus Kinase 1 (JAK1) transduces cytokine-receptor signaling, and JAK inhibitors (Jakinibs), including JAK1-specific filgotinib, break inflammatory cycles in autoimmunity. Here, we report in heterogeneous DC populations of multiple secondary lymphoid organs that JAK1 promotes peripheral T cell tolerance during experimental autoimmune encephalomyelitis (EAE). Mice harboring DC-specific JAK1 deletion exhibit elevated peripheral CD4+ T cell expansion, less regulatory T cells (Tregs), and worse EAE outcomes, whereas adoptive DC transfer ameliorates EAE pathogenesis by inducing peripheral Tregs, programmed cell death ligand 1 (PD-L1) dependently. This tolerogenic program is substantially reduced upon the transfer of JAK1-deficient DCs. DC-intrinsic IFN-γ-JAK1-STAT1 signaling induces PD-L1, which is required for DCs to convert CD4+ T cells into Tregs in vitro and attenuated upon JAK1 deficiency and filgotinib treatment. Thus, DC-intrinsic JAK1 promotes peripheral tolerance, suggesting potential unwarranted DC-mediated effects of Jakinibs in autoimmune diseases.Entities:
Keywords: JAK1; autoimmunity; dendritic cells; peripheral tolerance; regulatory T cells
Mesh:
Substances:
Year: 2022 PMID: 35196494 DOI: 10.1016/j.celrep.2022.110420
Source DB: PubMed Journal: Cell Rep Impact factor: 9.995